美国 · SEC FORM 4
Cytek Biosciences, Inc.
CTKB · Nasdaq · CIK 0001831915 · Healthcare · Medical Devices
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
70 同一窗口内观察到的 Form 4 交易行
0 sales · 70 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-06-02 · McCombe William D. · $97.3K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Yan MingCHIEF TECHNOLOGY OFFICER
○○○○○
Jiang WenbinPRESIDENT AND CEO
○○○○
McCombe William D.Chief Financial Officer
○○○○
Holder MichaelDirector
○○○
Chin RichardDirector
○○
Busque PhilippeSVP, GLOBAL SALES AND SERVICES
○○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-06-02 · McCombe William D..
近期 Form 4 活动
0买入
0卖出
143其他 Form 4 交易行
36SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他70 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 5,215,595
- 上期报告
- 5,242,079
- 日均成交量
- 1,666,297
- 回补天数
- 3.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-06-02 | McCombe William D. | 买入 (P) | Common Stock | 35,000 | USD 2.78 | USD 97,300 | SEC 申报 ↗ |
| 2022-03-15 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 241,727 | USD 12.27 | USD 2,965,990 | SEC 申报 ↗ |
| 2022-03-14 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 342,143 | USD 12.35 | USD 4,225,466 | SEC 申报 ↗ |
| 2022-03-11 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 337,492 | USD 12.77 | USD 4,309,773 | SEC 申报 ↗ |
| 2022-03-10 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 256,992 | USD 12.95 | USD 3,328,046 | SEC 申报 ↗ |
| 2022-03-09 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 40,154 | USD 12.99 | USD 521,600 | SEC 申报 ↗ |
| 2022-03-08 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 245,701 | USD 12.86 | USD 3,159,715 | SEC 申报 ↗ |
| 2022-03-07 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 337,901 | USD 12.61 | USD 4,260,932 | SEC 申报 ↗ |
| 2022-03-04 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 63,662 | USD 12.99 | USD 826,969 | SEC 申报 ↗ |
| 2022-03-02 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 138,255 | USD 12.89 | USD 1,782,107 | SEC 申报 ↗ |
| 2022-03-01 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 294,864 | USD 12.98 | USD 3,827,335 | SEC 申报 ↗ |
| 2022-02-28 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 8,746 | USD 12.97 | USD 113,436 | SEC 申报 ↗ |
| 2022-02-25 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 18,991 | USD 12.99 | USD 246,693 | SEC 申报 ↗ |
| 2022-02-24 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 186,467 | USD 13.03 | USD 2,429,665 | SEC 申报 ↗ |
| 2022-02-23 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 214,922 | USD 13.41 | USD 2,882,104 | SEC 申报 ↗ |
Form 4 申报证据
143 transaction lines in the latest 365-day window; 604 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Yan Ming | 期权行权／转换 (M) | Common Stock | 33,270 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-18 | Yan Ming | 代扣税 (F) | Common Stock | 8,088 | USD 4.67 | USD 37,771 | SEC 申报 ↗ |
| 2026-08-18 | McCombe William D. | 期权行权／转换 (M) | Common Stock | 35,420 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Yan Ming | 期权行权／转换 (M) | Common Stock | 33,270 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-18 | Yan Ming | 代扣税 (F) | Common Stock | 8,088 | USD 4.67 | USD 37,771 | SEC 申报 ↗ |
| 2026-08-18 | McCombe William D. | 期权行权／转换 (M) | Common Stock | 35,420 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-18 | McCombe William D. | 代扣税 (F) | Common Stock | 11,904 | USD 4.67 | USD 55,592 | SEC 申报 ↗ |
| 2026-08-18 | MUIR GLENN P | 期权行权／转换 (M) | Common Stock | 3,086 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-18 | Jiang Wenbin | 期权行权／转换 (M) | Common Stock | 120,095 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-18 | Jiang Wenbin | 代扣税 (F) | Common Stock | 36,269 | USD 4.67 | USD 169,376 | SEC 申报 ↗ |
| 2026-08-18 | Holder Michael | 期权行权／转换 (M) | Common Stock | 2,181 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-18 | Chin Richard | 期权行权／转换 (M) | Common Stock | 6,107 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-12 | Yan Ming | 赠与 (G) | Common Stock | 135,892 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-10 | NEFF DEBORAH J | 期权行权／转换 (M) | Common Stock | 43,973 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-10 | Imper Vera | 期权行权／转换 (M) | Common Stock | 43,973 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-10 | Holder Michael | 期权行权／转换 (M) | Common Stock | 43,973 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-10 | Ball Jack | 期权行权／转换 (M) | Common Stock | 43,973 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | Yan Ming | 期权行权／转换 (M) | Common Stock | 22,179 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | Yan Ming | 代扣税 (F) | Common Stock | 5,532 | USD 3.55 | USD 19,639 | SEC 申报 ↗ |
| 2026-05-18 | McCombe William D. | 期权行权／转换 (M) | Common Stock | 25,719 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | McCombe William D. | 代扣税 (F) | Common Stock | 9,229 | USD 3.55 | USD 32,763 | SEC 申报 ↗ |
| 2026-05-18 | Jiang Wenbin | 期权行权／转换 (M) | Common Stock | 80,062 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | Jiang Wenbin | 代扣税 (F) | Common Stock | 25,542 | USD 3.55 | USD 90,674 | SEC 申报 ↗ |
| 2026-05-18 | Holder Michael | 期权行权／转换 (M) | Common Stock | 1,454 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | Chin Richard | 期权行权／转换 (M) | Common Stock | 6,107 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | Busque Philippe | 期权行权／转换 (M) | Common Stock | 10,464 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | Busque Philippe | 代扣税 (F) | Common Stock | 2,685 | USD 3.55 | USD 9,532 | SEC 申报 ↗ |
| 2026-05-18 | Barnett Valerie | 期权行权／转换 (M) | Common Stock | 24,295 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-18 | Barnett Valerie | 代扣税 (F) | Common Stock | 8,719 | USD 3.55 | USD 30,952 | SEC 申报 ↗ |
| 2026-03-13 | Yan Ming | 赠与 (G) | Common Stock | 1,176,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-10 | Yan Ming | 期权行权／转换 (M) | Common Stock | 25,400 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-10 | Yan Ming | 代扣税 (F) | Common Stock | 7,731 | USD 4.23 | USD 32,702 | SEC 申报 ↗ |
| 2026-03-10 | McCombe William D. | 期权行权／转换 (M) | Common Stock | 23,721 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CTKB |
| CIK | 0001831915 |
| 行业 | Healthcare |
| 细分行业 | Medical Devices Yahoo Finance |
| SEC SIC | 3826 Laboratory Analytical Instruments |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 604 transaction lines from 2021-07-22 to 2026-08-18 27 P purchase lines · 75 S sale lines · 502 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.